Philippe Touraine

Country flagFrance

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Childhood-onset growth-hormone deficiency (GHD) requires growth-hormone therapy (GHT) to optimize final height. GHT may also have benefits after final height is achieved, notably on bone. The objective of this retrospective single-center observational cohort study of patients who had persistent GHD after achieving their final height was to assess bone parameters at the transition to adult care and then more than 6 months later (6.08 (3.33–10.25) years). Bone mineral density (BMD) and Z-score at the lumbar spine and hip were determined. Of 162 patients transitioned to adult care in 1994–2021, 105 received GHT for longer than 6 months (GHT group) and 57 received either no GHT or GHT for less than 6 months (no-GHT group); however, BMD and Z-score data from both evaluations were available for only a minority of patients. Lumbar-spine BMD was significantly higher at the second evaluation in the GHT group than in the no-GHT group ( P = 0.034). The lumbar-spine Z-scores at the first and second evaluations were −1.61 and −1.32 in the no-GHT group vs −1.09 and −0.61 in the GHT group ( P = 0.047 for the difference in median change over time between groups). Changes in BMD at the lumbar spine and in BMD and Z-score at the femoral neck were not significantly different between the two groups. These results suggest beneficial effects of continued GHT in patients with persistent GHD after final height attainment, adding evidence to continue GH therapy during and after the transition period. Plain language summary Children with insufficient growth-hormone levels are given growth-hormone injections to allow them to gain height. Once the final height is achieved, the treatment is often stopped. However, further treatment during the transition to adulthood may have benefits, notably on bone.

Year:

2025

Treatment of classic congenital adrenal hyperplasia (CAH) is directed at replacing deficient hormones and reducing androgen excess. However, even in the era of early diagnosis and lifelong hormonal substitution, the presence of CAH is still associated with numerous complications and also with increased mortality. The aim of this article was to create an authoritative and balanced review concerning cardiometabolic risk in patients with CAH. The authors searched all major databases and scanned reference lists of all potentially eligible articles to find relevant articles. The risk was compared with that in other forms of adrenal insufficiency. The reviewed articles, most of which were published recently, provided conflicting results, which can be partially explained by differences in the inclusion criteria and treatment, small sample sizes, and gene–environment interactions. However, many studies showed that the presence of CAH is associated with an increased risk of weight gain, worsening of insulin sensitivity, high blood pressure, endothelial dysfunction, early atherosclerotic changes in the vascular wall, and left ventricular diastolic dysfunction. These complications were more consistently reported in patients with classic than nonclassic CAH and were in part related to hormonal and functional abnormalities associated with this disorder and/or to the impact of overtreatment and undertreatment. An analysis of available studies suggests that individuals with classic CAH are at increased cardiometabolic risk. Excess cardiovascular and metabolic morbidity is likely multifactorial, related to glucocorticoid overtreatment, imperfect adrenal hormone replacement therapy, androgen excess, and adrenomedullary failure. Cardiometabolic effects of new therapeutic approaches require future targeted studies.

Year:

2024

Objective The diagnosis of premature ovarian insufficiency (POI) is a traumatic event for many patients that involves poor fertility prognosis. After such diagnosis, spontaneous pregnancies are rare. The alternatives for building a family are oocyte donation, embryo donation, and adoption. However, we have few information on how many women with POI finally built a family after the diagnosis and which alternative they chose. Design We performed a cross-sectional, descriptive study. Methods We conducted a survey of all the women who consulted for POI in the department of endocrinology and reproductive medicine at la Pitié Salpêtrière between May 31, 1991, and January 12, 2021. We included patients who continued to be followed up regularly by our department or were contacted by mail or phone between June and September 2021. We excluded patients with Turner syndrome and POI secondary to oncological treatment and patients under 18 at the time of the survey. Results 985 patients were referred to the department for POI, and 324 patients were finally analyzed. 41% of the women who wanted to build a family had children after the diagnosis: 53.9% by oocyte donation, 1 woman by embryo donation, 5.6% after ovarian stimulation, 13.5% by adoption, and 25.8% who had spontaneous pregnancy after a mean time of 2.5 years. Spontaneous pregnancy rate was 8.6% in the whole cohort. Conclusions Having children after a diagnosis of POI is not uncommon but more often results from oocyte donation. This study will provide enlightened information for newly diagnosed women on the possibilities to build a family after POI diagnosis.

Year:

2023

Collaborators (2)

Henrik Falhammar

Karolinska Institutet

SWEDEN
View details

Nicole Reisch

LMU University Hospital

GERMANY
View details